SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 305 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,503,734 | +8.5% | 12,405 | +2.5% | 0.06% | +12.0% |
| Q2 2023 | $1,386,265 | -17.7% | 12,105 | -0.9% | 0.05% | -10.7% |
| Q1 2023 | $1,683,456 | +1.5% | 12,214 | -4.6% | 0.06% | -5.1% |
| Q4 2022 | $1,659,142 | +16.5% | 12,804 | -0.6% | 0.06% | +9.3% |
| Q3 2022 | $1,424,000 | +41.7% | 12,886 | -3.9% | 0.05% | +54.3% |
| Q2 2022 | $1,005,000 | -5.7% | 13,408 | -1.8% | 0.04% | +9.4% |
| Q1 2022 | $1,066,000 | -14.1% | 13,650 | -0.9% | 0.03% | -8.6% |
| Q4 2021 | $1,241,000 | -1.0% | 13,780 | +1.6% | 0.04% | -7.9% |
| Q3 2021 | $1,254,000 | +19.3% | 13,560 | +0.3% | 0.04% | +22.6% |
| Q2 2021 | $1,051,000 | -3.0% | 13,520 | -7.1% | 0.03% | -11.4% |
| Q1 2021 | $1,084,000 | -56.8% | 14,548 | -1.2% | 0.04% | -58.8% |
| Q4 2020 | $2,511,000 | +20.5% | 14,729 | -0.7% | 0.08% | +3.7% |
| Q3 2020 | $2,083,000 | -13.2% | 14,830 | -1.0% | 0.08% | -21.9% |
| Q2 2020 | $2,401,000 | +16.4% | 14,973 | -29.0% | 0.10% | -13.9% |
| Q1 2020 | $2,063,000 | -24.5% | 21,085 | -0.5% | 0.12% | +6.1% |
| Q4 2019 | $2,733,000 | +71.5% | 21,182 | +0.1% | 0.12% | +49.4% |
| Q3 2019 | $1,594,000 | -52.4% | 21,167 | -3.9% | 0.08% | -55.2% |
| Q2 2019 | $3,348,000 | +29.2% | 22,036 | +1.4% | 0.17% | +17.0% |
| Q1 2019 | $2,591,000 | +6.8% | 21,741 | -2.2% | 0.15% | -16.5% |
| Q4 2018 | $2,426,000 | -34.0% | 22,226 | -2.3% | 0.18% | -18.5% |
| Q3 2018 | $3,674,000 | +23.0% | 22,746 | +0.7% | 0.22% | +8.0% |
| Q2 2018 | $2,986,000 | +80.8% | 22,588 | +1.3% | 0.20% | +65.3% |
| Q1 2018 | $1,652,000 | +34.5% | 22,300 | +1.0% | 0.12% | +27.4% |
| Q4 2017 | $1,228,000 | +26.9% | 22,070 | +3.4% | 0.10% | +18.8% |
| Q3 2017 | $968,000 | +35.6% | 21,350 | +0.8% | 0.08% | +19.4% |
| Q2 2017 | $714,000 | +86.9% | 21,180 | +64.2% | 0.07% | +81.1% |
| Q1 2017 | $382,000 | +16.5% | 12,895 | +7.8% | 0.04% | +2.8% |
| Q4 2016 | $328,000 | -41.8% | 11,965 | +30.3% | 0.04% | -46.3% |
| Q3 2016 | $564,000 | +75.2% | 9,180 | +9.9% | 0.07% | +48.9% |
| Q4 2015 | $322,000 | – | 8,350 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |